4DMT Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 91
Employees
  • Stock Symbol
  • FDMT
Stock Symbol
  • Share Price
  • $47.42
  • (As of Friday Closing)

4DMT General Information

Description

4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 5858 Horton Street
  • Suite 455
  • Emeryville, CA 94608
  • United States
+1 (510) 000-0000

4DMT Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

4DMT Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$47.42 $46.71 $35.01 - $51.00 $1.26B 26.5M 298K -$4.14

4DMT Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
Revenue 16,619 6,986 14,130 5,790
EBITDA (51,237) (49,806) (9,704) (10,686)
Net Income (52,261) (49,306) (9,551) (11,223)
Total Assets 98,192 58,234 96,969 27,320
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

4DMT Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial

4DMT Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial

4DMT Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pi
Biotechnology
Emeryville, CA
91 As of 2020
00000
0000 0000-00-00
00000000 00000

00000000

liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000000000000
Gaithersburg, MD
00 As of 0000
000.00
00000000 000.00

00000 00

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat c
0000 000000000
South San Francisco, CA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

4DMT Competitors (69)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000 000.00
00000 000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
000000 Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
You’re viewing 5 of 69 competitors. Get the full list »

4DMT Executive Team (11)

Name Title Board Seat Contact Info
David Kirn MD Chief Executive Officer & Founder
August Moretti JD Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Fred Kamal Ph.D Chief Technology Officer, Technology & Chief Operating Officer, Operations
Theresa Janke Founder & Chief Strategy Officer, Strategy
Peter Francis MD Chief Scientific Officer
You’re viewing 5 of 11 executive team members. Get the full list »

4DMT Board Members (14)

Name Representing Role Since
Charles Theuer MD Self Board Member 000 0000
David Schaffer Ph.D Self Co-Founder, Chief Scientific Advisor & Board Member 000 0000
Jacob Chacko MD Self Board Member 000 0000
John Milligan Ph.D Self Chairman & Board Member 000 0000
Nancy Miller-Rich Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

4DMT Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

4DMT Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial